An increased expression of interleukin-23 has been observed in patients with pyoderma gangrenosum, leading to the use of ustekinumab as a therapeutic option. We report the successful use of ustekinumab in three patients with treatment-resistant pyoderma gangrenosum of varying clinical presentations.
INTRODUCTION
We report three cases of recalcitrant pyoderma gangrenosum with differing disease activity in which ustekinumab, a human monoclonal antibody directed against interleukin (IL)-12 and IL-23, was used successfully with no adverse effects. In all cases a diagnosis of pyoderma gangrenosum was based on clinical features and skin biopsies that revealed a mixed inflammatory dermal infiltrate in the absence of vasculitis or infective organisms. Wound swab testing and tissue cultures were used to exclude bacterial, mycobacterial, fungal or viral infection as the primary cause. None of our patients had an associated underlying systemic illness.
CASE PRESENTATION Patient 1
A 42-year-old woman developed an area of ulceration and necrosis of the skin following minor trauma to the dorsal right hand and forearm. Over a 3.5-year period from June 2011 more than 20 new lesions developed on her arms, legs, lower face and lower abdomen, occurring as inflammatory plaques that rapidly developed into painful necrotic ulcers (Fig. 1) . During one hospital admission a deep ulcer 6 cm in diameter with violaceous undermined edges developed within a few days of having an intravenous cannula inserted into the left cubital fossa. On another occasion the patient applied a small amount of an antiseptic liquid (Dettol; Reckitt Benckiser, Sydney, New South Wales, Australia) to the dorsum of the hand and within several days an ulcer developed, exposing the underlying tendons and resulting in permanent functional damage.
Many immunosuppressive medications were used in combination (Table S1 ). In the setting of long-term immunosuppression she developed significant complications including central obesity, pulmonary aspergillosis, septicaemia, osteoporosis and depression. Due to her severe pain regular narcotic analgesia was required.
In January 2015, ustekinumab was commenced, initially 90 mg at weeks 0 and 4 and then every 6 weeks, later changed to 45 mg every 3 weeks. The patient's weight was 120 kg. At 3 months a significant improvement was noted, with a reduction in ulcer size and pain and fewer new lesions. At 24 months the condition remains well controlled on ustekinumab, prednisolone, mycophenolate mofetil, i.v. immunoglobulin and dapsone, with all previous lesions healed and occasional new ulcers that are small and heal rapidly.
Patient 2
A 57-year-old woman was diagnosed with pyoderma gangrenosum in 2011 after presenting with a painful non-healing ulcer for 6 months on the left shin following superficial trauma. The ulcer slowly enlarged over the next 4 years and a second adjacent lesion developed, resulting in a deep wound over most of the left anterior lower leg (Fig. 2 2014 further ulcers arose on the right leg within areas of palpable purpura that appeared at this site. The purpuric rash was not biopsied due to concerns of pathergy; however, clinically it was a small-vessel vasculitis, appearing several days after the commencement of flucloxacillin and resolving soon after ceasing the antibiotic. At no other time did the patient present with palpable purpura. Numerous combinations of immunosuppressants were administered (Table S1 ). Unfortunately, this did not prevent the need for long-term oral prednisolone and i.v. methyl-prednisolone on five occasions. Two attempts at split skin grafting with i.v. steroids preoperatively failed to re-epithelialise the ulcers, although pathergy did not develop at the donor sites. She suffered from multiple complications secondary to long-term immunosuppression. These included recurrent cellulitis, septicaemia, avascular necrosis of the hip and multiple drug-resistant organisms (Pseudomonas aeruginosa and Klebsiella pneumoniae) resulting in numerous hospital admissions. Regular narcotic analgesia was required for pain relief.
In December 2015 ustekinumab was commenced (90 mg at weeks 0 and 4, then every 8 weeks, and then 45 mg every 4 weeks). The patient's weight was 128 kg. At 6 months a distinct improvement was noticed, with a reduction in the size of the ulcers and a decrease in pain and analgesic requirements. Ongoing healing and far fewer episodes of secondary cellulitis have been observed on maintenance treatment at 13 months with ustekinumab, prednisolone, mycophenolate and dapsone.
Patient 3
A 36-year-old woman presented to the dermatology clinic in October 2014 with a 12-month history of painful ulcers of the lower legs and breast (Fig. 3) . In November 2015 she required high doses of oral prednisolone, leading to multiple complications including central obesity, osteoporosis and diabetes. Other medications (Table S1 ) either failed to heal the ulcers or resulted in unacceptable toxicity.
Ustekinumab was commenced at a dose of 90 mg every 8 weeks and then 45 mg every 4 weeks (after initial dosing of 90 mg at weeks 0 and 4). The patient weighed 125 kg. Within 5 months the ulcer sizes and pain had significantly ameliorated. The dose of prednisolone was successfully weaned to 5 mg daily, with a normalisation of blood sugar levels. At 14 months of ongoing treatment with ustekinumab, prednisolone, mycophenolate and intravenous immunoglobulin, there is almost complete healing of the ulceration. 
DISCUSSION
The treatment of pyoderma gangrenosum presents a significant challenge to clinicians. Although various treatment algorithms have been proposed these are largely based on low levels of evidence. 1 Prolonged courses of systemic steroids and cyclosporin remain the main options for treatment and there is a need for safer and more effective alternatives.
The demonstration that immune mediators are overexpressed in pyoderma gangrenosum lesions has raised the prospect of targeted therapy with biological agents. IL-1b, IL-8, IL-17, IL-23, IL-32, tumour necrosis factor alpha and matrix metalloproteinases 2 and 9 may play important roles in the inflammatory process. 2 Infliximab and etanercept were found to be effective in some but not all cases of pyoderma gangrenosum. It has now been observed that tumour necrosis factor alpha is not always increased in patients with pyoderma gangrenosum. 3 Recently the successful use of canakinumab points towards IL-1b targeted therapy as a promising approach.
3,4
Guenova and colleagues 5 demonstrated there was an elevated expression of IL-23 (but not of IL-17 or IL-12) in the skin of a patient with pyoderma gangrenosum compared with healthy skin, and the authors subsequently treated the patient with ustekinumab, a human monoclonal antibody that targets the p40 subunit of IL-12 and IL-23. The ulcer healed over 14 weeks of treatment and had not relapsed 6 months after stopping the medication. Since the publication of this case the use of ustekinumab in treating pyoderma gangrenosum has been reported in four additional cases. [5] [6] [7] [8] [9] . In the previous case reports a response to treatment with ustekinumab was observed within a period of a few days to 16 weeks, with complete healing occurring between 10 weeks and 8 months. Our experience suggests that a therapeutic trial of up to 6 months and a treatment course beyond 12 months may be required. Furthermore, the dose of ustekinumab necessary to treat pyoderma gangrenosum appears to be higher than the standard dosing regimen used in the treatment of psoriasis.
Combination therapy is an accepted strategy in treating pyoderma gangrenosum and so the efficacy of ustekinumab as monotherapy is as yet unknown. Interestingly, Guenova and colleagues 5 used ustekinumab with the addition of topical tacrolimus only. Ustekinumab was administered early in this patient, approximately 1 month after the ulcer developed. It may be the case that pyoderma gangrenosum becomes increasingly refractory to treatment the longer the ulcers remain unhealed. This possibility would support the early introduction of biological therapies such as ustekinumab.
CONCLUSION
Ustekinumab appears to be a safe and effective treatment for pyoderma gangrenosum. Clinical efficacy may not be observed for up to 6 months and higher than standard doses and a course over 12 months may be required. The possibility that early treatment may prevent the development of chronic refractory ulcers should be considered.
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